Obesity Matters Advocates for Public Listing of Wegovy, Highlighting the Need for Health Equity
Obesity Matters has taken a significant step forward in advocating for the inclusion of Wegovy for weight loss on public health plans in Canada through a comprehensive patient survey. This initiative not only seeks to improve access to obesity treatments but also to elevate the voices of those who have often been silenced in healthcare discussions. The survey, which garnered responses from over 100 patients within a few weeks, unanimously supported the public reimbursement of Wegovy for weight loss and underscored the urgency for policymakers to address health equity in obesity management. Add to this calls from doctors and it is clear that there continues to be a gap in Canada’s health care system.
Amplifying Patient Voices
The overwhelming response from the survey paints a vivid picture of the struggles faced by individuals managing obesity. One respondent powerfully stated, “I want my life back. Obesity has robbed me of this. I am not a lazy slob sitting on my ass eating crap. I do not deserve to have obesity.” Such personal accounts highlight the stigma and misunderstanding surrounding obesity and emphasize the need for patient voices to be heard and respected in the policy-making process.
The Economic and Health Benefits of Wegovy® for Weight Loss
Patients clearly articulated the benefits of Wegovy, stressing its role as a critical component of an obesity treatment plan. They pointed out the inconsistency in healthcare coverage, where surgical interventions are covered but not medical ones. The survey highlighted potential savings in healthcare costs through reduced rates of diabetes, cardiovascular diseases, and other comorbid conditions associated with obesity. “The cost of comprehensive obesity treatment would surely be recouped by the reduction of illness burden of the associated comorbidities,” one patient noted.
Addressing Health Inequities
Survey participants voiced a strong demand for health equity, stating that health is a human right in Canada, yet good health is often treated as a privilege rather than a right for those with obesity. They called for comprehensive support including the coverage of medications, dieticians, and the education of healthcare providers to be trauma-informed. This approach not only aims to save money but also to improve patient outcomes significantly.
A Call for Inclusive Health Policy
The survey responses make a compelling case for normalizing and destigmatizing obesity treatment. Comparing the need for obesity medications to those used for quitting smoking, patients argued for equal access to treatment options for those willing to follow a treatment plan. “People managing overweight and obesity have been silenced too long and need their voices heard and their requests for health equity implemented by policymakers,” a participant urged.
Conclusion
The patient survey conducted by Obesity Matters is a clarion call for policymakers to implement inclusive and equitable health policies that recognize obesity as a chronic disease requiring comprehensive treatment. By amplifying patient voices and advocating for public reimbursement of treatments like Wegovy, Obesity Matters is pushing for a transformative change in the healthcare landscape, ensuring that all Canadians have equitable access to the treatments they need.
FAQs
What is Wegovy®?
Wegovy® (semaglutide) injection 2.4 mg is a prescription semaglutide weight loss medication designed to reduce the risk of major cardiovascular events in adults with heart disease and obesity, that also increases the feeling of fullness in patients. It has also been shown to reduce cravings for certain high-fat food items. In Canada, Wegovy® is approved for use alongside a reduced-calorie diet and increased physical activity to aid weight loss in individuals with a BMI of:
- 30 kg/m² or greater, or
- 27 kg/m² or greater, with at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes, or dyslipidemia).
Wegovy® is also approved for individuals aged 12 years and older with obesity or those with weight-related medical conditions. It should not be used with other semaglutide-based products.
Lastly, Wegovy® reduces a human’s blood sugar by supporting insulin release when blood sugar is high.
Is Wegovy® available in Canada?
Yes it is! Wegovy® became available in Canada on May 6th, 2024. Presently, it is available via a healthcare practitioner who prescribes and recommends the semaglutide injection for individuals who are defined as “overweight” (i.e. a BMI greater than 27), and/or those who have a medical condition directly correlated to their weight.
What is the price of Wegovy® in Canada?
Presently, Wegovy® is available for $400 per month in Canada.
Wegovy® vs. Ozempic: What’s the Difference?
Although Wegovy and Ozempic both utilize injectable semaglutide, they differ in their core intent and focus. Specifically, Wegovy has been approved for usage of obese individuals 12 years and older, while Ozempic is designed and has been approved to lower blood sugar for those struggling with type 2 diabetes.
What are the side effects of Wegovy®?
Although side effects differ on the individual, Wegovy® may cause:
- Nausea, and, in some cases, vomiting.
- Constipation
- Diarrhea
- Stomach pain and/or acid reflux
- Headaches
- Tiredness
- Dizziness
- Stomach swelling
And, for people with diabetes, Wegovy® may cause low blood sugar.
